Omeros announces results for narsoplimab expanded access program
Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) ...
Stocktwits on MSN3d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
FierceBiotech4d
Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...